Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly's $2.3B Ajax drug works ‘right out of the gate’
The early data showed the novel JAK2 inhibitor “started working right out of the gate, with a good safety profile,” Lilly’s Jake Van Naarden said.
Angus Liu
Jun 13, 2026 11:15am
Fierce Pharma
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
Jun 11, 2026 7:00am
ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide
Jun 10, 2026 11:10am
GLP-1s may combat depression through a mood-boosting gut microbe
Jun 10, 2026 11:00am
Lilly licenses AlzeCure Alzheimer’s asset for $1B biobucks
Jun 9, 2026 10:16am
Roche sticks with €600M diagnostics investment in Germany
Jun 9, 2026 8:00am
